Weill Cornell Medicine investigators made an unexpected finding about how the immune system normally suppresses inappropriate ...
MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...
Don't overcomplicate things for yourself.
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa ...
Responding to reports from peer reviewers is a crucial part of scientific publishing, but early-career researchers are rarely taught about this process.
Related Digital and funds affiliated with Blackstone have secured the equity and debt financing needed to fund the $16 ...